JURSW Volume 8
Permanent URI for this collectionhttps://hdl.handle.net/20.500.12588/1747
Browse
Browsing JURSW Volume 8 by Department "Biomedical Engineering and Chemical Engineering"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item Detecting Ventilator Associated Pneumonia Through On-board Endotracheal Tube Diagnostics(UTSA Office of Undergraduate Research, 2022-12) Johnson, Benjamin; Christenson, Chase; Rahman, Mikayla; Guda, TejaVentilator-associated pneumonia (VAP) is a burdensome healthcare-associated infection which puts 54% of intensive care unit (ICU) life support patients across the United States at serious risk. Half of all antibiotics in the ICU are prescribed for VAP, but due to widespread inadequate treatment (up to 30% of cases), mortality rates remain as high as 24-76%. Inadequate treatment stems from lack of diagnostic and monitoring capacity. The current standard of detection is a non-specific complete blood count (CBC) completed every 24 hours. CBCs may take up to an additional 24 hours to process, allowing the infection to grow and become more difficult to treat for a total of 48 hours. To address these issues, this study conceptualizes a passively operated, high-fidelity, and high-frequency bacterial monitoring device to detect the presence and concentrations of bacteria commonly encountered in VAP. Electrochemical Impedance Spectroscopy (EIS) has been utilized extensively in electrochemical industry applications such as acid battery testing and, more recently, as a sensitive method for biofouling quantification. However, EIS has not been implemented clinically. The selected design will use a specialized EIS sensor to analyze mucosal excretions of intubated patients and quantify the bacteria present. This technology can alert physicians of infection 24-48 hours earlier than currently possible, allowing patients to receive treatment faster and thus potentially reducing their length of stay (LOS) in the ICU by ~6 days. Our findings project that this approach would lower each VAP patient’s treatment cost by approximately $24,000 and would save healthcare systems $3,600 per ICU patient (rates and estimates determined in 2019).Item Stem Cells used for Tissue Engineering of Articular Cartilage: Literature Review(UTSA Office of Undergraduate Research, 2022-12) Advano, Dhillon R.; Abu-Lail, Nehal I.Adult articular cartilage (AC) has a limited self-healing capacity. Cartilage defects lead to osteoarthritis (OA) characterized by severe pain and impaired mobility. Currently, there are no approved treatments for OA that successfully reverse or heal structural defects permanently. Although techniques such as microfracture, arthroplasty and subchondral drilling have been effective at treating small to intermediate sized AC defects over the short term, a long-term solution for OA is still necessary. In recent years, research has focused on tissue engineering of articular cartilage (TEAC) as a potential treatment option for OA. TEAC therapies utilizing chondrocytes such as autologous chondrocyte implantation (ACI) are promising but are limited by their complexity, high cost and inability to promote the formation of healthy hyaline AC. Due to the limitations of ACI, stem cells have been investigated as an alternative cell source for TEAC. To engineer AC, stem cells are allowed to differentiate on/in a scaffold in a bioreactor that controls chemical, physical and biological cues to support the chondrogenic potential of the stem cells. The use of stem cells provides numerous advantages as treatment costs can be lowered, the number of required surgeries can be reduced and high-quality AC can be formed. Mesenchymal stem cells (MSC) in particular are advantageous in that they are easily available and can be extracted from a diverse range of tissues including, bone marrow, adipose, and synovium. Each type of MSC have their own advantages and disadvantages but generally each of them possess high chondrogenic potential and immunosuppressive capacities. Induced pluripotent stem cells (iPSC) have also been recognized as a promising cell type for TEAC due to their unlimited proliferation and self-renewal capacities. Ultimately, each cell source has potential for use in TEAC therapies but further studies comparing cell sources are required before a gold standard can be determined. This review summarizes the pros and cons for potential use of each stem cell source in TEAC. The review is not meant to be comprehensive of the current literature.